Only a proportion of breast cancer families has germline mutations in the BRCA1 or BRCA2 genes, suggesting the presence of additional susceptibility genes. Finding such genes by linkage analysis has turned out to be difficult due to the genetic heterogeneity of the disease, phenocopies and incomplete penetrance of the mutations. Isolated populations may be helpful in reducing the level of genetic heterogeneity and in providing useful starting points for further genetic analyses. Here, we report results from a genome-wide linkage analysis of 14 high-risk breast cancer families from Finland. These families tested negative for BRCA1 and BRCA2 germline mutations and showed no linkage to the 13q21 region, recently proposed as an additional susceptibility locus. Suggestive linkage was seen at marker D2S364 (2q32) with a parametric two-point LOD score of 1.61 (h ¼ 0), and an LOD score of 2.49 in nonparametric analyses. Additional genotyping of a 40 cM chromosomal region surrounding the region of interest yielded a maximum parametric two-point LOD score of 1.80 (h ¼ 0) at D2S2262 and a nonparametric LOD score of 3.11 at an adjacent novel marker 11291M1 in BAC RP11-67G7. A nonparametric multipoint LOD score of 3.20 was seen at 11291M1 under the assumption of dominant inheritance. While not providing proof of linkage considering the small number of families and large number of laboratory and statistical analyses performed, these results warrant further studies of the 2q32 chromosomal region as a candidate breast cancer susceptibility locus. Both linkage and association studies are likely to be useful, particularly in other isolated populations.
Introduction
The two major breast cancer susceptibility genes, BRCA1 and BRCA2, account for a majority of high-risk families with both early-onset breast cancer and ovarian cancer. 1 However, most of the families with less than six cases of female breast cancer and no ovarian cancer do not carry BRCA1 or BRCA2 mutations that can be detected by conventional sequencing. 1 -5 Furthermore, the proportion of breast cancer families attributable to these genes may also vary among different populations. For example, a large fraction of breast cancer in Ashkenazi Jewish families can be explained by prevalent founder mutations in the BRCA1 and BRCA2 genes, 6 whereas in the Finnish population mutations in these genes seem to be less frequent. 5, 7, 8 Many efforts have been made to discover additional, previously unknown susceptibility genes by linkage or association analyses. Positive linkage has been observed at chromosome region 8p12 -p22 in two German families. 9 Recently, we presented evidence for a novel putative breast cancer susceptibility locus at chromosome region 13q21. 10 Neither of these findings could be confirmed by the Breast Cancer Linkage Consortium, 11, 12 suggesting that these linkages may either represent population-, phenotype-or family cohort-specific effects or simply type I or II error. Indeed, our recent reanalyses of the 13q21 -q22 linkage data suggest that linkage was primarily seen in Finnish families that exhibited only breast cancer and relatively few affected cases (S Juo, personal communication). The aim of this study was to perform a genome-wide linkage (GWL) search for additional susceptibility loci in a putatively homogeneous group of 14 Finnish breast cancer families without BRCA1 or BRCA2 involvement, and with no evidence of linkage to the 13q21 site, followed by fine mapping of interesting chromosomal regions. Using relatively homogeneous populations, such as the Finns, as the target for this study, was likely to reduce the extent of genetic heterogeneity that usually makes linkage analyses of complex diseases difficult. Since recent segregation analyses have suggested an involvement of a recessive breast cancer gene, 13 -15 we also tested both recessive and dominant models of inheritance.
Materials and methods

Families
In all, 14 Finnish breast cancer families collected at the Helsinki and Oulu University Hospitals were included in the study. All families had at least three breast cancer cases with DNA available for genotyping. Both Oulu and Helsinki families were previously tested negative for BRCA1 and BRCA2 mutations by heteroduplex analysis (ie DGGE, SSCP or CSGE), protein truncation test and linkage analysis (data not shown). 5, 7, 8 In addition, the Oulu families were excluded having large rearrangements by Southern blot analysis. 16 All families were screened for CHEK2 mutation 1100delC, which is present in 1.1 -1.4% of the normal population and has recently been identified as a lowpenetrance allele with a two-fold increased breast cancer risk. 17, 18 Some individuals in families 178 and 277 were found to carry this mutation; 18 however, due to the incomplete segregation and the low penetrance of the allele, these families were included in this study. Of the 14 families now investigated, 10 were included in our previous 13q-linkage study. None of the families showed linkage to chromosome region 13q21. 10 Figure 1 ). Each marker was independently amplified according to standard PCR protocol. The PCR products were then pooled and run on the ABI 377 DNA Sequencer. Electrophoretic data were analyzed by two independent individuals using Genescan and Genotyper software programs (Applied Biosystems, Foster City, CA, USA). The allele sizes were determined using the CEPH family member 134702. For fine mapping, an additional set of 34 markers, spanning a 40 cM chromosomal region from 2q24 to 2q33, was used ( Figure 1 ) (www.marshfieldclinic.org). The primer sequences for four markers in BAC RP11-67G7 are as follows: 11291M1 forward, 5
0 . The heterozygosities for these markers are 60, 71, 70 and 64%, respectively. PCR reactions were performed in a 15 ml volume containing 20 ng of genomic DNA, 0.33 mM each primer, 0.25 mM each dNTP, 2.5 mM MgCl 2 , 10 mM Tris-HCl, 50 mM KCl and 0.5 U Taq polymerase PCR amplification was performed using the GeneAmp 9600 or 9700 thermocyclers (Applied Biosystems, Foster City, CA, USA). PCR cycling conditions were as follows: 951C for 12 min; followed by 10 cycles of 941C for 15 s, 551C for 15 s, 721C for 30 s; and 20 cycles of 891C for 15 s, 551C for 15 s, 721C for 30 s, with a final extension of 721C for 10 min.
Statistical analyses
Genotyping data were checked for Mendelian inconsistency using the genetic analysis system and PedCheck programs. 19 Any marker violating the rules of Mendelian transmission was double checked by the genotyping laboratory. Ambiguous marker genotypes were deleted. The biological relationships were also examined using the RelCheck computer program. 20 The program uses the genotypic information of autosomal markers and calculates the likelihoods to infer the true relationship of a putative sibling pair. Five relationships were considered: monozygotic twins, parental/offspring, full sibs, half-sibs and unrelated individuals.
Allele frequencies were calculated from all genotyped family members in the genome-wide analysis by the Gconvert program (http://www2.qimr.edu.au/davidD). For the fine-mapping markers on 2q, we also included additional 270 unrelated Finnish controls to obtain better allele frequency estimations. Both parametric and nonparametric analyses were performed under both dominant and recessive inheritance models. For the dominant parametric analysis, the CASH model 21 as modified by
Easton et al 22 was used. In brief, this model specifies dominant inheritance of a susceptibility allele and 14 agespecific liabilities (seven age-specific cumulative risks for unaffecteds, and another seven age-specific densities for affecteds). The population frequency of a disease allele is determined to be 0.0033. For the recessive model, the parameters were adopted from Cui et al. 14 The recessive model specifies a disease allele frequency of 0.063, and the Genome-wide linkage scan in breast cancer families P Huusko et al risk of a homozygote is 50% by age 40 years and near certainty by age 60 years. Similarly, a total of 14 agespecific liability classes were used in the recessive model. Nonparametric analyses were performed using a newly developed pseudomarker approach, 23, 24 which approximates a 'model-free' affected relative pair analysis, but maintains an important property of LOD score analysis: pedigree correlations between all relatives are considered jointly, and the pedigree is not broken into sets of all possible relative pairs. The nonparametric dominant inheritance analysis assumed that all affecteds are gene carriers, and the disease allele is infinitesimally rare, according to the pseudomarker strategy. 24 Similarly, the nonparametric recessive inheritance analysis assumed a rare disease allele and no phenocopies. Both parametric and nonparametric analyses (ie pseudomarker approach) were carried out using the FASTLINK program. 25 -27 Sliding multipoint analysis was conducted in the region of most significant two-point LOD scores by using the FASTLINK program. In all analyses, the breast cancer cases were coded as affected and all other cancer cases as unaffected.
Results
In the GWL analyses, assuming dominant inheritance, marker D2S364 at chromosome 2q32 gave the highest parametric two-point LOD score of 1.61 (y ¼ 0). The second highest LOD score of 1.12 (y ¼ 0) was seen for marker D9S283 at 9q21. Marker D2S364 also showed the highest LOD score (2.49) in the nonparametric pseudomarker analysis, using a dominant mode of inheritance (Figure 1 ). Under the assumption of recessive inheritance, seven out of 398 markers showed LOD scores above one in parametric analysis. These markers were D2S367 (2p22), D2S364 (2q32), D3S1304 (3p26), D11S4177 (11p15), D19S921 (19q13), DXS1001 (Xq24) and DXS1227 (Xq27). The LOD score at D2S364 was 1.77 (y ¼ 0.05), while the highest LOD score of 1.96 (y ¼ 0.05) was seen at marker DXS1001 (Xq24). In the nonparametric recessive analysis, the following five markers had LOD scores above one: D2S364 (2q32), D3S1304 (3p26), D9S1690 (9q31), D11S902 (11p15) and DXS1073 (Xq28). The LOD score at D2S364 was 1.43, while the highest LOD score of 1.72 was seen at D11S902 (11p15) (data not shown).
Since the 2q32 region was most consistently positive in the statistical analyses, we chose to focus on additional genotyping at this region, and performed linkage analyses assuming a dominant mode of inheritance. We genotyped 34 additional markers covering approximately 40 cM around the peak marker D2S364. A maximum parametric two-point LOD score, 1.80 (y ¼ 0), was observed for marker D2S2262 at 2q32.2. The highest LOD score of 3.11 was seen at marker 11291M1 in nonparametric analysis. This marker was developed using a polymorphic nucleotide repeat in BAC RP11-67G7, which maps to chromosome region 2q32.1 in between markers D2S364 and D2S2273. The highest multipoint LOD score was 3.20, seen at the same marker (Figure 2 ). The HOMOG program was used to test for evidence of genetic heterogeneity for markers D2S364 and 11291M1 which yielded the highest LOD scores. The results from HOMOG gave no significant evidence of genetic heterogeneity. However, it is well known that the A-test used in HOMOG has low power to detect heterogeneity in complex diseases. Thus, the negative results from HOMOG do not necessarily mean that no heterogeneity exists in these families.
According to the recombinations seen in one of the most informative families, 3009, the critical region spans from marker D2S2177 to D2S117 (Figure 3) . No common haplotypes between the linked families were seen (data Genome-wide linkage scan in breast cancer families P Huusko et al not shown), suggesting multiple different mutations in these families.
Discussion
We report in this study suggestive evidence of a novel breast cancer susceptibility locus at chromosome region 2q32 in Finnish families without involvement of BRCA1, BRCA2 or chromosome region 13q21. The existence of a novel breast cancer susceptibility gene was initially supported by both parametric (LOD score 1.61) and nonparametric (LOD score 2.49) analyses of the GWL data. Further evidence for linkage was obtained from additional genotyping with more markers, providing the final nonparametric multipoint LOD score of 3.20.
The entire area of mild linkage positivity spans about 40 cM from D2S156 (2q24) to D2S325 (2q33). The number of known genes in this region is 194. The 5 cM core region from D2S384 to D2S2262, where the LOD scores are above one in both parametric and nonparametric analyses, includes 28 known genes. Several candidate genes of potential biological interest are located here, ITGAV a member of integrin gene family, as well as PMS1, one of the HNPCC (hereditary nonpolyposis colorectal cancer) genes.
The sequence in this region is not complete and additional genes are likely to be found within the gaps.
Regarding the involvement of recessive genes in breast cancer, 13 -15 chromosome region Xq24 may be interesting.
Previously, candidate loci for prostate (HPC-X) and testicular cancer have been linked to this chromosomal arm, but substantially more distally, at the Xq27 region. 28, 29 Based on the prior experience in replicating linkage results of complex diseases from one population to another, it is possible that 2q32 will not turn out to be a major predisposition locus in more heterogeneous sample sets available to most investigators. In fact, based on the paucity of published linkage results in breast cancer, it is increasingly likely that no region in the human genome will display overwhelmingly positive LOD scores in the general Western European or US populations. Obviously, after the BRCA1 and BRCA2 genes are excluded, many factors may contribute to the familial clustering of breast cancer. It is possible that some of the remaining familial breast cancers are due to chance clustering of apparently sporadic cases. 30 cancer is conferred by a large number of alleles. 34 The contribution of low-penetrance susceptibility genes, such as CHEK2 17, 18 to breast cancer causation appears very important. Considering these multiple genetic and nongenetic causes that may explain familial clustering of breast cancer, further efforts to investigate the reported 2q32 linkage are needed before any conclusions on the significance of the reported data at this locus are drawn. These analyses should incorporate both linkage-and nonlinkagebased methods, including association analyses and studies of candidate genes in the region. Studies in other isolated populations would be particularly informative. In summary, we present preliminary evidence of linkage in Finnish breast cancer families to a susceptibility locus at the chromosomal region 2q32. The presence of a gene predisposing to breast cancer at this locus will obviously have to be confirmed by an independent study, involving refined linkage mapping, genetic association and studies of candidate genes. Finally, analyses of this region at 2q as a target for somatic alterations in sporadic breast cancer may be informative.
